Physicochemical Properties
| Molecular Formula | C24H28N6O |
| Molecular Weight | 416.518724441528 |
| Exact Mass | 416.23 |
| Elemental Analysis | C, 69.21; H, 6.78; N, 20.18; O, 3.84 |
| CAS # | 1401728-56-0 |
| PubChem CID | 68379135 |
| Appearance | White to yellow solid powder |
| LogP | 3.5 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 5 |
| Heavy Atom Count | 31 |
| Complexity | 578 |
| Defined Atom Stereocenter Count | 0 |
| InChi Key | HXPQWNPLNIEJOW-UHFFFAOYSA-N |
| InChi Code | InChI=1S/C24H28N6O/c1-4-21-20(22-26-15(2)13-16(3)30(22)29-21)14-17-5-7-18(8-6-17)23-27-28-24(31-23)19-9-11-25-12-10-19/h5-8,13,19,25H,4,9-12,14H2,1-3H3 |
| Chemical Name | 2-[4-[(2-ethyl-5,7-dimethylpyrazolo[1,5-a]pyrimidin-3-yl)methyl]phenyl]-5-piperidin-4-yl-1,3,4-oxadiazole |
| Synonyms | NE52QQ57; NE 52-QQ57; NE52-QQ57; NE-52-QQ57; NE-52QQ57; NE 52QQ57 |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| Targets | TNF-α; IL-1β; IL-6; iNOS; NO |
| ln Vitro | NE 52-QQ57 efficiently inhibits GPR4-mediated cAMP accumulation (IC50 26.8 nM) in HEK293 cells)[2]. |
| ln Vivo | NE 52-QQ57 (Compound 13) demonstrates a notable reduction in inflammation in the rat antigen-induced arthritis model following oral treatment at a dose of 30 mg/kg bid for 20 days[1]. As shown in the rat complete Freund's adjuvant model, NE 52-QQ57 (30 mg/kg bid po for 4 days) also inhibits pain and angiogenesis in the mouse chamber model[1]. |
| Animal Protocol |
Female FVB mice (8-10 weeks) 30 mg/kg Oral, 4 days, bid |
| References |
[1]. Development of Selective, Orally Active GPR4 Antagonists with Modulatory Effects on Nociception, Inflammation, and Angiogenesis. J Med Chem. 2017 May 11;60(9):3672-3683. [2]. CNS distribution, signalling properties and central effects of G-protein coupled receptor 4. Neuropharmacology. 2018 Aug;138:381-392. |
Solubility Data
| Solubility (In Vitro) |
DMSO: ~20 mg/mL (~48.0 mM) Ethanol: ~45 mg/mL |
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2 mg/mL (4.80 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2 mg/mL (4.80 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2 mg/mL (4.80 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4008 mL | 12.0042 mL | 24.0085 mL | |
| 5 mM | 0.4802 mL | 2.4008 mL | 4.8017 mL | |
| 10 mM | 0.2401 mL | 1.2004 mL | 2.4008 mL |